MacLeod C., Fowler A., Duval P., D'Costa I., Dalrymple C., Elliott P., Atkinson K., Firth I., Carter J.
Department of Radiation Oncology, Royal Prince Alfred Hospital and King George V Hospital, Camperdown, New South Wales, Australia; Department of Gynaecological Oncology, Royal Prince Alfred Hospital and King George V Hospital, Camperdown, New South Wales, Australia; Department of Radiation Oncology, St. Vincent's Hospital, Darlinghurst, New South Wales, Australia; Department of Radiation Oncology, Peter MacCallum Hospital, Melbourne, Victoria, Australia.
Int J Gynecol Cancer. 1999 May;9(3):247-255. doi: 10.1046/j.1525-1438.1999.99026.x.
The purpose of this study was to evaluate patient selection, local control, survival and late toxicity of posthysterectomy adjuvant radiotherapy and compare adjuvant external beam therapy and high-dose rate (HDR) brachytherapy versus HDR brachytherapy alone. A retrospective analysis was performed on a series of 225 patients with endometrial cancer treated with external beam radiotherapy and HDR brachytherapy or HDR brachytherapy alone posthysterectomy from 1985 to June 1993. Of these 225 patients, 82 received external beam radiotherapy and brachytherapy and 143 received brachytherapy alone. The HDR fraction size was 8.5 Gy prescribed to the mucosal surface; two fractions were given after external beam and four fractions if brachytherapy alone was used. The median follow-up was 6.9 years. The patients who received combined external beam and brachytherapy had higher stage and grade tumors. The survival outcome was similar for either group when matched for stage. Overall relapse-free survival at five years was 96% and 81%, respectively for brachytherapy alone and combined adjuvant therapy. Pelvic recurrence was seen in 2.7% of patients. Toxicity was more common with external beam radiotherapy and brachytherapy compared to brachytherapy alone (45.1% vs 23.1%, P = 0.003). However, moderate or severe toxicity was rare but again was more common in the combined radiotherapy group (8.5% vs 2.1%, P = 0.04). There was a non-significant trend to increased toxicity after lymphadenectomy and external beam radiotherapy compared with patients who did not have a staging lymphadenectomy prior to external beam radiotherapy (62% vs 38%, P = 0.16). Adjuvant radiotherapy can be individualized and be based upon the information provided by the pathological specimens, which excluded external beam radiotherapy if a lymphadenectomy was performed and there was no evidence of extra-uterine disease. This study found more toxicity associated with adjuvant radiotherapy compared with other studies, but this may reflect different reporting criteria. There was more toxicity related to external beam radiotherapy and brachytherapy compared to brachytherapy alone. The two HDR brachytherapy protocols used in this series appear effective and safe.
本研究的目的是评估子宫切除术后辅助放疗的患者选择、局部控制、生存率和晚期毒性,并比较辅助外照射放疗与高剂量率(HDR)近距离放疗联合应用与单纯HDR近距离放疗的效果。对1985年至1993年6月期间接受子宫切除术后外照射放疗和HDR近距离放疗或单纯HDR近距离放疗的225例子宫内膜癌患者进行了回顾性分析。在这225例患者中,82例接受了外照射放疗和近距离放疗,143例仅接受了近距离放疗。HDR分割剂量为黏膜表面8.5 Gy;外照射后给予2次分割剂量,若仅采用近距离放疗则给予4次分割剂量。中位随访时间为6.9年。接受外照射放疗与近距离放疗联合治疗的患者肿瘤分期和分级更高。当根据分期进行匹配时,两组的生存结果相似。单纯近距离放疗组和辅助联合治疗组的五年无复发生存率分别为96%和81%。2.7%的患者出现盆腔复发。与单纯近距离放疗相比,外照射放疗与近距离放疗联合应用时毒性更常见(45.1%对23.1%,P = 0.003)。然而,中度或重度毒性很少见,但在联合放疗组中再次更为常见(8.5%对2.1%,P = 0.04)。与在外照射放疗前未进行分期淋巴结清扫的患者相比,淋巴结清扫和外照射放疗后毒性有增加的趋势,但差异无统计学意义(62%对38%,P = 0.16)。辅助放疗可以根据病理标本提供的信息进行个体化,若进行了淋巴结清扫且没有子宫外疾病的证据,则可排除外照射放疗。本研究发现与其他研究相比,辅助放疗的毒性更大,但这可能反映了不同的报告标准。与单纯近距离放疗相比,外照射放疗与近距离放疗联合应用时毒性更大。本系列研究中使用的两种HDR近距离放疗方案似乎有效且安全。